Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)

RATIONALE: CSF1R tyrosine kinase inhibitors (TKI) and antibodies yield response rates and tumor control in patients with diffuse type tenosynovial giant cell tumors (dTGCT). The long term management of patients with dTGCT treated with TKI is however not known. PATIENTS AND METHODS: We conducted a re...

Descripción completa

Detalles Bibliográficos
Autores principales: Brahmi, Mehdi, Cassier, Philippe, Dufresne, Armelle, Chabaud, Sylvie, Karanian, Marie, Meurgey, Alexandra, Bouhamama, Amine, Gouin, Francois, Vaz, Gualter, Garret, Jerome, Sunyach, Marie-Pierre, Dupré, Aurélien, Marec-Berard, Perrine, Corradini, Nadège, Perol, David, Ray-Coquard, Isabelle, Blay, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239463/
https://www.ncbi.nlm.nih.gov/pubmed/32433669
http://dx.doi.org/10.1371/journal.pone.0233046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239463/
https://www.ncbi.nlm.nih.gov/pubmed/32433669
http://dx.doi.org/10.1371/journal.pone.0233046

Ejemplares similares